Journal of Clinical Oncology
Articles in this Issue
Real world experience with immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC): 5-year single center analysis.
e16169 Background: The HIMALAYA and IMbrave150 trials introduced two groundbreaking ICI combinations for treating HCC, showing the potential to significan...
A phase 1b/2, open-label study of selective Axl, Mer and CSF1R inhibitor adrixetinib (Q702) in combination with intravenous pembrolizumab in patients with selected advanced solid tumors: Results of a phase 1 study (QRNT-008).
2606 Background: Adrixetinib (Q702) is an orally administrated novel Axl/Mer/CSF1R tyrosine kinase inhibitor for which the...
Camrelizumab plus chemotherapy or apatinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma: A double-cohort phase II study.
e18005 Background: Targeting vascular endothelial growth factor receptor (VEGFR) may synergistically enhance the antitumor effects of immune checkpoint in...
Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).
4003 Background: Claudin18.2 (CLDN18.2) has emerged as a promising therapeutic target in G/GEJC. Recently reported results showed...
Predicting survivorship and caregiver burden in multiple myeloma (MM) using machine learning (ML): Insights from a large, national, prospective study.
e13661 Background: MM survival has improved significantly, resulting in increased survivorship and caregiver burden and is crucial to understand the real-...
ctDNA versus 18F-FDG PET-CT in predicting long-term disease control in patients with advanced melanoma undergoing immune checkpoint blockade therapy.
9559 Background: Imaging remains the gold standard for assessing response to systemic immunotherapy in patients with advanced melanoma. Several studies ha...
Tumor stage at diagnosis as an indicator of cancer screening efficacy in diverse populations.
e13805 Background: Efficacy of cancer screening depends on effective communication of its benefits and on low threshold access. Screening program acceptan...
Treatment-related toxicities of antibody-drug conjugates in breast cancer: A Bayesian network meta-analysis.
e15015 Background: Antibody-drug conjugates (ADCs) have demonstrated significant efficacy in treating patients with breast cancer. However, the toxicity v...
A phase 1b/2, safety lead-in and dose-expansion trial of ivosidenib plus durvalumab and gemcitabine/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation.
TPS4219 Background: Cholangiocarcinomas (CCAs) are often advanced and incurable at the time of diagnosis. The phase 3 TOPAZ-1 trial showed improved OS and...
Disparities in demographics and outcomes of breast cancer in females undergoing mastectomy in rural vs. urban teaching centers.
583 Background: Breast cancer (BC) sensitization, awareness, and increased screening have led to significant improvements in prevention, management, and s...
Real-world survival outcomes with ivosidenib in Chinese patients with IDH1-mutated intrahepatic cholangiocarcinoma.
e16227 Background: The phase III ClarIDHy trial led to FDA approval of ivosidenib as a therapeutic option for locally advanced or metastatic cholangiocarc...
Renal cancer mortality and disability worldwide: Insights from the Global Burden of Disease (1990–2021).
e16509 Background: Renal cancer (RC) is a major contributor of cancer-related deaths worldwide, with significant regional disparities. Understanding globa...
Investigating the tumor microenvironment and neoadjuvant therapy response in HER2-positive breast cancer with invasive micropapillary carcinoma component.
e12621 Background: Invasive micropapillary carcinoma (IMPC) is a rare histopathological subtype of breast carcinoma (BC) that shows a high rate of HER2-po...
Comparison of clinicopathological features in early-onset breast cancer patients with and without pathogenic genetic mutation.
e13179 Background: Early-onset breast cancer (EOBC), particularly in women under 40, has been increasing. Approximately, 10% of women with breast cancer c...
Whole brain radiotherapy and intrathecal injection of thiotepa, combined with systemic treatment for the primary tumor, to treat solid tumor leptomeningeal metastasis: A prospective, single center, single arm, phase II clinical study.
2027 Background: To evaluate the efficacy and toxicity of a triple therapy regimen consisting of Hippocampal-sparing whole-brain radiotherapy (HS-WBRT), i...
Effect of EGR1-mediated glutamine metabolic reprogramming through mTOR signaling pathway on pancreatic stellate cell activation and pancreatic cancer liver metastasis.
e16359 Background: Pancreatic cancer is one of the most malignant cancers with an occult presentation and difficult diagnosis. Liver metastasis, which acc...
Utility of plasma cell-free DNA and tissue next generation sequencing (NGS) in detecting genetic mutations in non-small cell lung cancer (NSCLC).
e20514 Background: NSCLC is defined by molecular alterations driving tumor progression and therapeutic response. Genetic profiling traditionally relies on...
Integrative analysis of tumor microenvironment in advanced pancreatic cancer: Unraveling genomic and immune landscape for targeted therapies.
4182 Background: An understanding of genotype and immunophenotype interactions in advanced pancreatic ductal adenocarcinoma (PDAC) is important in designi...
Sex-stratified mortality and disability-adjusted life years (DALYs) due to gastric cancer among older adults (70+) from 1990 to 2021: A global burden of disease study.
e16134 Background: Gastric cancer is a malignant disease characterized by the uncontrolled growth of cells in the stomach lining and is a global health co...
Overall survival and quality of life superiority in modern phase III oncology trials.
11015 Background: The use of alternative endpoints, such as progression-free survival, has increased over time in phase III randomized clinical trials (RC...
Screening for social needs and providing enhanced support: Preliminary findings from a multi-center research study.
e13812 Background: Recognition of the impact of social needs on health outcomes has grown. To address cancer health inequities in the Washington, DC area,...
Use of steroid-sparing agents (SSAs) for immune-related adverse events (irAEs) in patients (pts) discussed at a multidisciplinary immune-related adverse event (irAE) tumor board.
e24112 Background: SSAs are standard of care for steroid-refractory irAEs from immune checkpoint inhibitors. Due to the paucity of high-quality evidence,...
Prognosis of isolated groin recurrence following sentinel lymph node biopsy in primary node-negative vulvar cancer.
e17650 Background: In early-stage vulvar cancer, sentinel lymph node biopsy (SNB) is an accepted method for surgical staging of the groin lymph nodes. How...
Open-label, single-arm, single-center phase 1b/2 clinical study of fruquintinib combined with trastuzumab and XELOX in the first-line treatment of advanced HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
TPS4203 Background: Trastuzumab plus chemotherapy has significantly prolonged survival in patients with HER2-positive gastric and gastroesophageal junctio...
Concurrent mutations in DNA damage repair genes <i>BRCA1</i> , <i>POLE</i> , <i>ATM</i> and <i>FANCA</i> to predict overall and progression-free survival for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with chemotherapy in combination with dual checkpoint inhibition in the CCTG randomized PA.7 trial.
4178 Background: CCTG PA.7 (NCT02879318) was a randomized phase II trial comparing gemcitabine (G) and nab-paclitaxel (N) with and without dual immune che...